Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
Last trade$9.54
Day change-$0.21 (-2.15%)
Day range$9.34 – $10.11
Volume342,859
Market cap$647M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$647.28M
Price / earnings
—
Price / book
1.58×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.39×
Profitability
Earnings per share
-$3.32
Return on assets
-47.82%
Return on equity
-53.8%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8.81×
Quick ratio
8.81×
Cash ratio
1.6×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$162.75M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BCAX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$19.24M
$14.18M
$12.74M
$8.13M
$7.7M
$7.22M
$7.46M
$6.75M
Research and development
$56.48M
$45.77M
$47.5M
$32.99M
$32.98M
$24.8M
$34.33M
$19.88M
Total operating expenses
$75.71M
$59.95M
$60.24M
$41.12M
$40.68M
$32.02M
$41.79M
$26.64M
Operating income
-$75.71M
-$59.95M
-$60.24M
-$41.12M
-$40.68M
-$32.02M
-$41.79M
-$26.64M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$71.2M
-$55.38M
-$56.16M
-$37.33M
-$36.29M
-$27.34M
-$36.77M
-$20.77M
Income taxes
$54K
$61K
$52K
$53K
$40K
$52K
$72K
$186K
Net income
-$71.25M
-$55.44M
-$56.21M
-$37.39M
-$36.33M
-$27.39M
-$36.85M
-$20.96M
Net income attributable to common shareholders
-$71.25M
-$55.44M
-$56.21M
-$37.39M
-$36.33M
-$27.39M
-$36.85M
-$20.96M
EBITDA
-$75.65M
-$59.91M
-$60.2M
-$41.08M
-$40.65M
-$32M
-$41.77M
-$26.62M
Basic earnings per share
-$1.04
-$0.82
-$0.93
-$0.68
-$0.67
-$0.50
-$0.68
-$0.38
Diluted earnings per share
-$1.04
-$0.82
-$0.93
-$0.68
-$0.67
-$0.50
-$0.68
-$0.38
Recent news
Company coverage with links to the original publishers.
Bicara Therapeutics CEO Claire Mazumdar sold 15,000 shares worth approximately $301,000 on May 18, 2026, through a pre-arranged Rule 10b5-1 trading plan adopted in February 2025. The sale reduced her direct holdings by 4%, but she retains 362,152 shares and 146,107 options, indicating continued substantial alignment with the company. The transaction appears routine for liquidity purposes rather than a sign of concern about the company's outlook.
Bicara Therapeutics (NASDAQ: BCAX) successfully closed an oversubscribed public offering, raising approximately $172.5 million in gross proceeds through the sale of 8,581,250 common shares and 2,200,000 pre-funded warrants. The underwriters fully exercised their option to purchase additional shares. The company plans to use the proceeds to advance its lead program ficerafusp alfa, a first-in-class bifunctional antibody for solid tumors, including regulatory filing and commercial launch preparations, manufacturing costs, and clinical development acceleration.
Bicara Therapeutics priced a $150 million underwritten public offering of 7.175 million common shares at $16.00 per share and 2.2 million pre-funded warrants. The company plans to use proceeds to advance its lead candidate ficerafusp alfa, build commercial infrastructure, accelerate development in head and neck cancer, and fund manufacturing and expansion efforts. The offering is expected to close on February 26, 2026.
Bicara Therapeutics (NASDAQ: BCAX), a clinical-stage biopharmaceutical company, announced a proposed underwritten public offering of $150 million in common stock with a 30-day option for underwriters to purchase an additional $22.5 million. The company plans to use proceeds to advance its lead drug ficerafusp alfa, build commercial infrastructure, and support regulatory filings and commercial launch efforts.
Bicara Therapeutics will present at the J.P. Morgan 2026 Healthcare Conference, highlighting its lead program ficerafusp alfa, a bifunctional antibody designed to treat solid tumor cancers by targeting EGFR and TGF-β.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.